XENOTHERA receives approval for first in man Kidney Transplant Clinical Trial
Nantes, September 11th, 2019 – XENOTHERA announces it has received Czech Republic regulatory...
More
XENOTHERA presents at ESOT 2019
XENOTHERA will participate at ESOT 2019 that will take place...
More
XENOTHERA announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.
Nantes, June 21st, 2019 – XENOTHERA announces receivability after its submission of a Clinical...
MoreXenothera Announces Publication in European Journal of Clinical Investigation on Immunological Mechanisms Underlining Use of LIS1
Kidney graft recipients receiving anti-lymphocyte globulins of animal origin undergo unwanted immune...
More
XENOTHERA to raise Series A
XENOTHERA has started to gather investors for a Series A round of...
More
XENOTHERA sponsors the realization of a fresco for the hospital by transplanted patients
Nantes, november 2017 The fresco, more than 8 meters long, has been...
More
XENOTHERA nominated for the Ernst&Young Entrepreneur Award
Nantes, September 2017 We have been selected for the 2017 entrepreneur awards...
More
Distinction: Jean-Paul SOULILLOU awarded for its international exceptional career and contribution in transplantation
August 25th, 2016 XENOTHERA, a young start-up from Nantes, is honored to...
More
Press Release: Start-up XENOTHERA closes a new capital increase above 2 million euros
June 10th, 2016 XENOTHERA, a young biotech who develops an innovative immunosuppressant,...
More